Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

Breast Neoplasms

Salivary Gland Neoplasms

Breast Neoplasms

HER2-positive Metastatic Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Salivary Gland Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Genomic Instability

Breast Neoplasms, Heart Failure

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Metastatic HER2-positive Breast Cancer With Brain Metastasis

Colorectal Neoplasms

Colorectal Neoplasms

Breast Neoplasms

Clinical Trials

I-SPY

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Opti-HER2

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

ZEPHIR-02

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

PHERGAIN-2

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

ProTarget

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

DARWINII

SCHOLAR-2

ZEPHIR

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Decrescendo

T-DM1

PATRICIA II

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

ROME

TRAEMOS

PREDIXIIHER2

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

KIARA

RESCUE

HERACLES

NATURE